REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Core Viewpoint - Tevogen Bio projects nearly $1 billion in revenue in its launch year for its specialty care pipeline, with a cumulative 5-year estimate between $18 billion and $22 billion, highlighting its innovative drug development model [1] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified T cell therapeutics to address infectious diseases and cancers, targeting significant unmet needs in large patient populations [3][4] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and several pending patents, two of which are related to artificial intelligence [3] Pipeline and Revenue Forecast - The revenue forecast includes $1 billion in the launch year for its oncology therapeutic area, with projections of $10 billion to $14 billion over the first five years [6] - Tevogen's product candidates include TVGN 489 for treating SARS-CoV-2 in various patient subgroups, as well as other therapeutics targeting cervical cancer, EBV-associated lymphomas, mouth and throat cancer, and multiple sclerosis [7]